CRISPR Therapeutics AG (CRSP) is listed on NASDAQ in Biotech Stocks. It is $57.69, -2.84%, with a $5.6B market cap. RSI is 59.7, neutral. The latest reported quarter beat estimates. Insiders were net buyers across the listed trades.
Technical Analysis
RSI (14) 59.7 Neutral
Market Cap $5.6B
Volume 1.3M
Fundamentals — 10-Q Q2 2026
Revenue $11.6M
Net Income $-214.1M
EPS $-2.22
Operating Margin -2126.6%
Net Margin -1839.4%
Debt / Equity 0.3x
P/E Ratio -26.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Patel Naimish | Chief Medical Officer | Sell | 3,786 | $55.62 | $210,577 | 2026 May 29 |
| Kasinger James R. | General Counsel and Secretary | Sell | 3,182 | $46.78 | $148,854 | 2026 Mar 23 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 10,020 | $46.78 | $468,736 | 2026 Mar 23 |
| Prasad Raju | Chief Financial Officer | Sell | 3,708 | $46.78 | $173,460 | 2026 Mar 23 |
| Patel Naimish | Chief Medical Officer | Sell | 3,150 | $48.26 | $152,019 | 2026 Mar 16 |
| Prasad Raju | Chief Financial Officer | Sell | 9,869 | $48.26 | $476,278 | 2026 Mar 16 |
| Kasinger James R. | General Counsel and Secretary | Sell | 3,450 | $48.26 | $166,497 | 2026 Mar 16 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 10,349 | $48.26 | $499,443 | 2026 Mar 16 |
| Kasinger James R. | General Counsel and Secretary | Sell | 2,800 | $52.80 | $147,840 | 2026 Mar 11 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 9,798 | $52.80 | $517,334 | 2026 Mar 11 |
| Prasad Raju | Chief Financial Officer | Sell | 10,000 | $55.95 | $559,521 | 2025 Dec 22 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 50,895 | $67.91 | $3.5M | 2025 Oct 17 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 4,242 | $66.60 | $282,517 | 2025 Oct 14 |
| Kasinger James R. | General Counsel and Secretary | Sell | 1,076 | $66.60 | $71,662 | 2025 Oct 14 |
| Kulkarni Samarth | Chief Executive Officer | Sell | 13,081 | $58.15 | $760,660 | 2025 Aug 18 |
| Treco Douglas A | Director | Buy | 20,000 | $57.03 | $1.1M | 2025 Aug 6 |
| George Simeon | Director | Buy | 989,812 | $52.03 | $51.5M | 2025 Jul 16 |
| Patel Naimish | Chief Medical Officer | Sell | 3,932 | $35.94 | $141,316 | 2025 May 29 |
| Kasinger James R. | General Counsel and Secretary | Sell | 3,185 | $41.23 | $131,318 | 2025 Mar 21 |
| Prasad Raju | Chief Financial Officer | Sell | 2,197 | $41.23 | $90,582 | 2025 Mar 21 |
Other Biotech Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $137.93 | 63.6 | $55.1B |
| | $432.33 | 66.2 | $233.7B |
| | $145.64 | 60.3 | $180.6B |
| | $43.12 | 53.6 | -- |
| | $118.23 | 51.7 | $9.8B |
| | $351.70 | 55.2 | $10.4B |
| | $54.45 | 50.2 | $13.5B |
Take CRSP further
- Browse Biotech Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put CRSP in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when CRISPR Therapeutics AG next reports.
Set alerts on CRSP
Get notified when CRISPR Therapeutics AG hits your price targets or technical conditions are met.
Get Started Free